Modulation of [3H]Dopamine Release from Rat Nucleus Accumbens by Neuropeptide Y May Involve a Sigma1-like Receptor1

  1. David T. Ault,
  2. Julie M. Radeff and
  3. Linda L. Werling
  1. Neuroscience Program and Department of Pharmacology, The George Washington University Medical Center, Washington, DC
     
    Next Section

    Abstract

    Sigma receptors are located in limbic areas, including the nucleus accumbens, where increased dopamine levels have been linked to psychosis and reinforcement. Neuropeptide Y (NPY) has been named as a possible endogenous ligand for a subpopulation of ς receptors on the basis of its ability to compete for ς receptor binding. Using a superfusion system, we found that NPY enhanced N-methyl-d-asparate-stimulated [3H]dopamine release in rat nucleus accumbens, whereas the prototypical ς agonist (+)pentazocine inhibited release. However, four ς antagonists, one of which is ς1 selective, as well as a Y receptor antagonist, all reversed the enhancement by NPY and the inhibition by (+)pentazocine. A ς2-selective antagonist had no effect on either NPY-mediated enhancement or (+)pentazocine-mediated inhibition. [Leu31,Pro34]NPY and NPY13–36also enhanced release, but the effects were not reversed by ς antagonists. Peptide YY did not mimic the effect of NPY. Our findings are consistent with the potential role of NPY as an endogenous ligand for a subtype of ς receptor with characteristics different from Y1, Y2 and Y3 receptors but sensitive to Ac-[3-(2,6-dichlorobenzyl)Tyr27,d-Thr32NPY-(27–36)amide. Our findings suggest a role for NPY, via ς receptors, in the regulation of dopamine levels in areas of brain critical to psychosis and reinforcement.

    Dopaminergic activity in the nucleus accumbens is believed to play a role in both the reinforcing abilities of drugs of abuse and the positive symptoms of schizophrenia. Therefore, receptors that modulate DA levels in the nucleus accumbens are potential targets for therapeutic management of drug abuse or schizophrenia. Sigma receptors have been localized to both motor and limbic areas containing high dopaminergic innervation, including the nucleus accumbens, in rodents (Gundlachet al., 1986; McLean and Weber, 1988), non-human primates (Leitner et al., 1994; Mash and Zabetian, 1992) and humans (Tam and Zhang, 1988). In the same motor and limbic brain regions, the interaction of ς receptors with DA neurons has been demonstrated (Ceci et al., 1988; Goldstein et al., 1989). In our laboratory, we have shown that agonists at ς receptors are capable of modulating DA release from rat striatal slices (Gonzalez-Alvear and Werling, 1994) and from nucleus accumbal and prefrontocortical slices of guinea pig brain (Weatherspoon et al., 1996).

    However, the role of ς receptors in physiological function is controversial. Originally identified by Martin et al.(1976), ς receptors were classified as a subtype of opioid receptor through which n-allylnormetazocine (SKF 10,047) produced psychotomimetic effects in chronic spinal dogs. Later, because of the similarity in both physiological effects and common binding properties, ς receptors were thought to be identical to PCP receptors. Since this initial classification, investigators have attempted to clarify the pharmacology and function of ς receptors. Sigma receptors are now recognized as a distinct class of receptors, and they are neither PCP receptors nor members of the opioid receptor family (Vaupel, 1982; Tam and Cook, 1984). Recent evidence has shown that there are at least two subtypes of ς receptors. The ς1site has a high affinity for (+)isomers of benzomorphans and haloperidol, whereas the ς2 site shows a slight preference for the (−) isomers of benzomorphans and also has a high affinity for haloperidol. Furthermore, Hanner et al. (1996)have recently reported the purification from guinea pig liver, molecular cloning and expression of a mammalian ς receptor in yeast. The pharmacology of the site is consistent with its identification as ς1, and it is a distinct receptor without significant sequence homology to any other identified receptor.

    Although compounds acting as agonists or antagonists have been developed for ς receptors, lack of identification of the endogenous ligand(s) at these sites has limited our understanding of ς receptor function. It has been proposed that NPY may be the endogenous ligand at a subpopulation of ς receptors. NPY can compete, in vivo, for the binding of radiolabeled ligands at a subpopulation of ς receptors, although the identification of this subpopulation as ς1- or ς2-like was not explored (Bouchardet al., 1993). However, in vitro experiments have yielded conflicting data on the ability of NPY to compete for ς binding (Roman et al., 1989; Tam and Mitchell, 1991). Furthermore, NPY activates a reasonably well characterized set of receptors called Y receptors. Autoradiographic studies suggest that the rat nucleus accumbens contains Y receptors mainly of the Y2subtype (Widdowson, 1993). However, the characterization of the Y3 receptor (Grundemar et al., 1991) and the more recent cloning of Y4 (Bard et al., 1995), Y5 (Gerald et al., 1996) and Y6(Gregor et al., 1996; Matsumoto et al., 1996;Weinberg et al., 1996) receptor subtypes suggest that other receptor types sensitive to NPY may also be functional in the nucleus accumbens. An increase in NPY-like immunoreactivity has been found in the cerebrospinal fluid of drug-free schizophrenic patients (Peterset al., 1990), which suggests that NPY may play a role in psychosis. In addition, microinjection of NPY into rat nucleus accumbens has been shown to generate place-preference behavior, a type of rewarding effect that is antagonized by the antipsychoticcis-flupenthixol (Josselyn and Beninger, 1993). NPY is also implicated in reinforcement of feeding behavior (Jewett et al., 1992).

    A subtype of NPY receptor has been suggested, on the basis of electrophysiological studies in rat hippocampal slices, to be identical to the ς1 receptor (Monnet et al., 1992a, b). In a previous study, we showed that in rat striatal slices, NPY enhanced dopamine release that was reversed by both ς receptor antagonists and PYX-1, a Y receptor antagonist, which suggests that there may be overlap in the population of receptors characterized as ς and the population of receptors characterized as Y (Ault and Werling, 1997). Our data showed that the enhancing effect of NPY on DA release occurred through a ς1-like receptor and not through Y1, Y2 or Y3 receptor subtypes. In the current study, we investigated the possible activity of NPY at ς receptors in the nucleus accumbens. We tested the ability of NPY to regulate NMDA-stimulated dopamine release in slices of rat nucleus accumbens. We then evaluated the abilities of various ς antagonists and PYX-1, a Y receptor antagonist, to reverse the effect of NPY. We also tested the ability of Y receptor subtype-selective NPY analogs to produce similar responses. By evaluating the effect of NPY on DA release and determining the receptor population through which it occurs in the nucleus accumbens, we may elucidate a possible means for improving DA imbalance in drug abuse and/or schizophrenia.

    Previous SectionNext Section

    Materials and Methods

    The following chemicals and reagents were kindly provided by or obtained from the following sources: NMDA, domperidone, nomifensine, nisoxetine, haloperidol, and 1,3-di(2-tolyl)guanidine (DTG) (Research Biochemicals International, Natick, MA), NPY (human, rat), PYY (Human), PYX-1, [Leu31,Pro34]NPY (Porcine) and NPY13–36 (porcine) (Peninsula Laboratories, Inc., Belmont, CA), fluoxetine and l-ascorbic acid (Sigma Chemical Co., St. Louis, MO), [3H]DA (Amersham Corp., Arlington Heights, IL), (+)pentazocine (Research Technology Branch, National Institute on Drug Abuse, Rockville, MD), DuP734 (Dr. William Tam and Dr. Rob Zaczek, DuPont Merck Pharmaceutical Co., Wilmington, DE), BD737 and BD1008 (Dr. Wayne Bowen, National Institute of Digestive Disorders and Kidney, Bethesda, MD) and BIMU-8 (Dr. Doug Bonhaus, Roche Bioscience, Palo Alto, CA).

    All experiments were carried out in accordance with the guidelines and the approval of the George Washington University Institutional Animal Use and Care Committee. Male Sprague-Dawley rats (Hilltop Lab Animals, Scottdale, PA) weighing 250 to 350 g were killed by decapitation, and the brains were removed to ice. Nuclei accumbens were dissected, chopped in two planes at right angles into 250 × 250-μm strips with a Sorvall T-2 tissue sectioner and suspended in MKB (127 mM NaCl, 5 mM KCl, 1.3 mM NaH2PO4, 2.5 mM CaCl2, 15 mM HEPES, 10 mM glucose, pH adjusted to 7.4 with NaOH) by trituration through a plastic pipette. Magnesium was always omitted from the buffer because of its physiological antagonism at the NMDA receptor/channel complex. Buffers were oxygenated throughout the experiments. After three washes in MKB, tissue was resuspended in 20 ml of MKB and incubated for 30 min with 0.1 mM ascorbic acid and 15 nM [3H]DA. Tissue was then washed twice in 20 ml MKB and once in MKB containing 10 μM nomifensine and 1 μM domperidone. These drugs were included in all subsequent steps to prevent reuptake of and feedback inhibition by the released [3H]DA. Because of low selectivity among monoamine reuptake mechanisms, the 30-min incubation period also included reuptake blockers for other monoamines (100 nM fluoxetine to block the serotonin reuptake mechanism and 100 nM nisoxetine to block the norepinephrine reuptake mechanism). Tissue was suspended a final time in MKB and distributed in 275-μl aliquots between glass-fiber discs into chambers of a BRANDEL superfusion apparatus (Gaithersburg, MD). MKB was superfused over tissue at a rate of 0.6 ml/min. A low stable base-line release of approximately 0.9%/min was established over a 30-min period. Tissue was then stimulated by a 2-min exposure to 25 μM NMDA (Stimulus 1; S1). The concentration was chosen for its position on the ascending portion of the concentration-response curve. Inflow was then returned to nonstimulating buffer during a 10-min interstimulus interval (ISI). If an inhibitor of release was being tested, it was included at this time. Tissue was then exposed to a second stimulus (S2) identical to the first but in the presence of potential inhibitor, as appropriate. If a drug was being tested as an enhancer, it was introduced during the S2. Inflow was once again returned to nonstimulating buffer before extraction of the remaining radioactivity in the tissue by a 45-min exposure to 0.2 N HCl at a reduced flow rate. Superfusates were collected at 2-min intervals in scintillation vials, and the glass-fiber filter discs and tissue were collected into the final vials. Released radioactivity was determined by liquid scintillation spectroscopy.

    All data were statistically analyzed as ratios (S2/S1). This made it possible to control for the change in responsiveness to the NMDA stimulation when comparing it with NMDA stimulation in the presence of a test drug. The mean S2/S1 for NMDA-stimulated [3H]DA release in the absence of any test drug was 0.49 ± 0.02 (N = 30). An enhancement by test drug would result in a higher ratio; an inhibition would result in a lower ratio. In this way, the effects of desensitization at NMDA receptors after S1 (Satheret al., 1992; Zilberter et al., 1991), or other differences in responsivity between tissue samples, are taken into account and therefore do not affect the comparison of treatments. In the results, data are expressed as radioactivity released above base line during the collection interval as a fraction of the total radioactivity in the tissue at the beginning of the collection interval (fractional release, %) or as a percentage of the radioactivity released by the control stimulus (% control-stimulated release). Data are presented as % control-stimulated release for facilitation of comparison across experiments. Under the experimental conditions used, the released radioactivity has been shown to be primarily dopamine (Werling et al., 1988). All statistical analyses were performed by two-way factorial ANOVA with post-hocDunnett’s. Statistical significance is considered to be achieved at P < .05.

    Previous SectionNext Section

    Results

    NPY, tested at a range of 0.1 to 100 nM, enhanced NMDA-stimulated [3H]DA release from rat striatal slices. The increase in release was concentration-dependent and exhibited a biphasic nature (fig. 1). A concentration of 10 nM NPY was chosen as the standard enhancement concentration for subsequent experiments. This concentration would be expected to produce >80% occupation of Y1, Y2 and Y3receptors.

    Figure 1
    View larger version:
    Figure 1

    Enhancement of NMDA-stimulated [3H]DA release by NPY in rat nucleus accumbal slices. Release of preloaded [3H]DA was stimulated by 25 μM NMDA in the presence of the indicated concentration of NPY. Data are expressed as radioactivity released above base line during the collection interval as a fraction of the total radioactivity in the tissue at the beginning of the interval. Data were analyzed by two-way factorial ANOVA withpost-hoc Dunnett’s. NPY enhancement was significantly different from control at 10, 30, and 100 nM. N = 6 for control and for 1, 3 and 10 nM concentrations of NPY. N= 3 for 0.1, 0.3, 30 and 100 nM concentrations of NPY.

    The effects of several sigma antagonists on the enhancement of NMDA-stimulated [3H]DA release by 10 nM NPY were tested. We chose concentrations of antagonists that would produce >50% occupation of their preferred receptor. The fivesigma antagonists chosen have Kivalues for sigma binding in the low nanomolar range. Haloperidol, DuP734, BD1008 and DTG each prevented the potentiation of release by NPY, whereas BIMU-8 had no effect (fig.2). Neither NPY nor any of the antagonists had an effect on basal (nonstimulated) release.

    Figure 2
    View larger version:
    Figure 2

    Reversal of NPY-mediated enhancement of NMDA-stimulated [3H]DA release bysigma1 antagonists. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 10 nM NPY in the presence or absence of thesigma antagonist indicated. Antagonists were tested at a concentration of 100 nM, except for BD1008, which was tested at a concentration of 10 nM. Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hoc Dunnett’s on untransformed data (S2/S1). *Significantly different from control. #Not significantly different from control. N = 6 for control and NPY alone. N = 3 for NPY with each antagonist.

    The effect of the nonselective Y receptor antagonist PYX-1 was also tested. This compound, tested at 10, 100 and 500 nM, reversed the enhancing effect of NPY in a concentration-dependent manner, and complete reversal occurred at a PYX-1 concentration of 500 nM (fig.3). PYX-1 had no effect on basal (nonstimulated) release.

    Figure 3
    View larger version:
    Figure 3

    Reversal of NPY-mediated enhancement of NMDA-stimulated [3H]DA release by PYX-1. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 10 nM NPY in the presence or absence of the indicated concentration of PYX-1. Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hoc Dunnett’s on untransformed data (S2/S1). *Significantly different from control. #Not significantly different from control. (N = 3)

    The contribution of the Y3 subtype can be determined by comparing the effect of PYY, which does not bind to Y3receptors, to that of NPY, which binds to Y1, Y2 and Y3 receptors. In contrast to NPY, PYY had no effect on NMDA-stimulated [3H]DA release when tested at 1, 10 or 100 nM (fig. 4, only highest concentration shown). Two NPY analogs were also tested at 1, 10 and 100 nM to evaluate further the possible contribution of Y receptor subtypes. [Leu31,Pro34]NPY binds to Y1 and Y3 receptors, and NPY13–36binds to Y2 and Y3 receptors. Both significantly enhanced NMDA-stimulated [3H]DA release at the 100 nM concentration (fig. 4, only highest concentration shown for each analog). Neither PYY nor the NPY analogs had an effect on basal release.

    Figure 4
    View larger version:
    Figure 4

    Effects of PYY and NPY analogs on NMDA-stimulated [3H]dopamine release. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 10 nM NPY, 100 nM PYY, 100 nM [Leu31,Pro34]NPY or 100 nM NPY13–36. Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hoc Dunnett’s on untransformed data (S2/S1). *Significantly different from control. N = 6 for control and NPY. N = 3 for other treatments.

    We also tested the actions of PYX-1 and three sigmaantagonists, DuP734, BIMU-8 and BD1008, on the enhancing effects of [Leu31,Pro34]NPY and NPY13–36. Concentrations of DuP734, BIMU-8 and BD1008 were the same as those used against NPY-mediated enhancement. A concentration of 500 nM PYX-1 was chosen because this completely reversed the enhancing effect of NPY. None of the three sigma antagonists was able to block [Leu31,Pro34]NPY- or NPY13–36-mediated enhancement. However, the Y receptor antagonist prevented the enhancement by both [Leu31,Pro34]NPY and NPY13–36. This suggests that [Leu31,Pro34]NPY and NPY13–36 are probably not acting through the same receptor as NPY to enhance stimulated release (figs.5 and 6).

    Figure 5
    View larger version:
    Figure 5

    Failure of sigma antagonists to reverse [Leu31,Pro34]NPY-mediated enhancement of NMDA-stimulated [3H]DA release. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 100 nM [Leu31,Pro34]NPY in the presence or absence of the antagonist indicated. Antagonists were tested at a concentration of 100 nM, except for BD1008, which was tested at 10 nM, and PYX-1, which was tested at 500 nM. Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hocDunnett’s on untransformed data (S2/S1). *Significantly different from control. #Not significantly different from control. (N= 3)

    Figure 6
    View larger version:
    Figure 6

    Failure of sigma antagonists to reverse NPY13–36-mediated enhancement of NMDA-stimulated [3H]DA release. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 100 nM NPY13–36 in the presence or absence of the antagonist indicated. Antagonists were tested at a concentration of 100 nM, except for BD1008, which was tested at 10 nM, and PYX-1, which was tested at 500 nM. Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hoc Dunnett’s on untransformed data (S2/S1). *Significantly different from control. #Not significantly different from control. (N = 3)

    Previous studies in this laboratory have shown that varioussigma antagonists can reverse BD737- and (+)pentazocine-mediated inhibition of NMDA-stimulated [3H]DA release in rat striatal slices (Gonzalez-Alvear and Werling, 1994) as well as in guinea pig nucleus accumbens and prefrontal cortex (Weatherspoon et al., 1996). In the current study we confirmed that 100 nM BD737 and 500 nM (+)pentazocine, concentrations that occupy >90% of ς1 receptors, also inhibit NMDA-stimulated [3H]DA release in slices of rat nucleus accumbens (fig. 7). The abilities of PYX-1 and three sigma antagonists, DuP734, BIMU-8 and BD1008, to modulate the inhibition of NMDA-stimulated [3H]DA release by (+)pentazocine were also tested (fig.7). Only the two sigma antagonists that act at the ς1 subtype (DuP734 and BD1008) prevented the inhibition; BIMU-8, a ς2-selective antagonist (Weatherspoon et al., 1996), had no effect. In addition, PYX-1 was able to prevent the inhibition by (+)pentazocine.

    Figure 7
    View larger version:
    Figure 7

    Reversal of (+)pentazocine-mediated inhibition of NMDA-stimulated [3H]DA release bysigma1 antagonists and PYX-1. Release of preloaded [3H]DA was stimulated by a 2-min exposure to 25 μM NMDA in the presence of 100 nM BD737 or 500 nM (+)pentazocine in the presence or absence of the antagonist indicated. Antagonists were tested at a concentration of 100 nM, except for BD1008 (10 nM) and PYX-1 (500 nM). Data are expressed as % control NMDA-stimulated release above base line. Data were analyzed by two-way factorial ANOVA with post-hoc Dunnett’s on untransformed data (S2/S1). *Significantly different from control. #Not significantly different from control. (N = 3)

    Previous SectionNext Section

    Discussion

    Several observations suggest that ς receptors may play a role in psychosis and in the reinforcing abilities of drugs of abuse by modulating DA levels in the nucleus accumbens. First, the greatest density of ς receptor binding sites is found in motor and limbic areas of many species (Gundlach et al., 1986). In humans, ς receptors are also located in motor and limbic areas and are particularly prominent in the nucleus accumbens (Weissman et al., 1988), the brain region believed to be involved in psychosis and reinforcement. Second, the nucleus accumbens is an area rich in DA, the neurotransmitter believed to modulate psychosis and reinforcement. Third, ς receptors have been shown to modulate DA levels in several brain regions, including rat striatum (Gonzalez-Alvear and Werling, 1994) and guinea pig nucleus accumbens and prefrontal cortex (Weatherspoon et al., 1996). Furthermore, some studies have shown changes in ς receptor density in post-mortem brain tissue of schizophrenics (Weissman et al., 1991; Shibuya et al., 1992). Thus a possible explanation for abnormal DA levels in psychosis and reinforcement is that ς receptors are present in inappropriate numbers or that they are inappropriately activated, leading to an increase in DA release. This explanation could be more easily investigated if an endogenous ligand for ς receptors were known.

    In the current study, we present results that are consistent with NPY being a potential endogenous ligand at a subpopulation of ς receptors that may, therefore, be involved in ς receptor mediation of psychosis and reinforcement. An increase in NPY-like immunoreactivity found in cerebrospinal fluid of drug-free schizophrenics (Peters et al., 1990) supports involvement in psychosis. NPY has also been shown to generate place-preference behavior, a type of rewarding effect, after its injection into the nucleus accumbens of rats (Josselyn and Beninger, 1993). This effect was reversed by the antipsychotic cis-flupenthixol and supports the involvement of NPY in reinforcement. Furthermore, NPY has been shown to increase food-seeking behavior in rats under conditions of satiety (Jewettet al., 1992). The motivation in seeking food by satiated rats is comparable to that in food-deprived rats, regardless of the amount of food already eaten (Jewett et al., 1995). It is possible that NPY is involved in the reinforcing abilities of drugs of abuse much as it is involved in the reinforcing ability of food.

    It was initially reported by Roman et al. (1989) that NPY, with an IC50 of approximately 10 nM, could compete with [3H]SKF10,047 for binding to ς receptors. Otherin vitro binding studies were unable to replicate these findings (Tam and Mitchell, 1991; Quirion et al., 1991). However, supporting evidence exists that suggests a commonality between ς and NPY receptors. These investigations include physiological studies on ion transport in jejunum (Riviere et al., 1993), on CRF-induced colonic motor activation (Junien et al., 1991) and on duodenal alkaline secretion (Pascaud et al., 1993) and electrophysiological studies showing that NPY can enhance NMDA-induced activation of CA3 pyramidal neurons and that this enhancement is reversible by haloperidol (Monnet et al., 1992a, b). Furthermore, we previously showed that NPY enhances DA release in rat striatal slices (Ault and Werling, 1997), an effect that is reversed by both ς receptor antagonists and PYX-1, a Y receptor antagonist. This suggests overlap in the population of receptors characterized as ς and the population of receptors characterized as Y. Our data showed that the enhancing ability of NPY on DA release occurs through a ς1-like receptor and not through Y1, Y2 or Y3 receptor subtypes. We now report similar results in slices of rat nucleus accumbens.

    In the current study, NPY enhanced NMDA-stimulated DA release in a concentration-dependent manner. This enhancement has a biphasic nature, consistent with its action at more than one receptor type. Because both the Y1-selective peptide [Leu31,Pro34]NPY and the Y2-selective peptide NPY13–36 also enhanced release, one might expect that a portion of the NPY-mediated enhancement was via these Y receptor subtypes. The concentration of NPY chosen for antagonist studies was 10 nM, which would have activated all receptor populations contributing to the biphasic response. At this concentration, NPY would be expected, on the basis of the IC50 of 10 nM reported by Roman et al. (1989), to occupy >80% of Y1, Y2 and Y3 receptors (Dumont et al., 1995) and 50% of ς receptors. IC50 values for NPY at Y receptors have been reported as 0.4 nM for Y1, 0.07 nM for Y2 and 1.8 nM for Y3 (Dumont et al., 1995; Higuchiet al., 1988). However, NPY-mediated, [Leu31,Pro34]NPY-mediated and NPY13–36-mediated enhancements were differentially affected by ς antagonists; whereas some ς antagonists completely reversed NPY-mediated effects, they had no effect on either [Leu31,Pro34]NPY-mediated or NPY13–36-mediated enhancement. Only those ς antagonists that are nonselective for ς subtype (BD1008, DTG and haloperidol) or are selective for the ς1 subtype (DuP734) completely reversed the NPY-mediated enhancement of stimulated release. Therefore, two receptor populations may participate in the enhancement by NPY. However, because full reversal is achieved by ς antagonists, these two receptor populations cannot be divided as ς and non-ς. In addition, they cannot be divided as ς1 and non-ς1, because full blockade of enhancement of release was achieved by the selective ς1 antagonist DuP734.

    The effect of NPY on NMDA-stimulated DA release is opposite to the effect seen in our previous studies with the ς agonists. BD737, which acts as a selective ς1 agonist at concentrations ≤100 nM, and (+)pentazocine both inhibited NMDA-stimulated DA release in rat striatum (Gonzalez-Alvear and Werling, 1994) and guinea pig nucleus accumbens and prefrontal cortex (Weatherspoon et al., 1996). Despite the opposite effect of NPY and ς agonists on NMDA-stimulated DA release, in the current experiments the enhancement of release by NPY was reversed by the same ς antagonists that reversed the inhibition of release by BD737 and (+)pentazocine. Four ς antagonists were able to reverse the enhancement of NMDA-stimulated DA release by NPY. The non-subtype-selective antagonists haveKi values as follows: BD1008, unspecified for subtype, 1.24 nM (Vilner et al., 1995); DTG, 12 nM at ς1 and 38 nM at ς2 (Walker et al., 1990); haloperidol, 1.9 nM at ς1 and 80 nM at ς2 (Vilner et al., 1992). The selective ς1 antagonist DuP734 has a Ki for ς1 receptors of 10 nM (Tam et al., 1992) and no binding at ς2 receptors at concentrations up to 1 μM. All four antagonists fully reversed NPY-mediated enhancement of NMDA-stimulated [3H]DA release. The ability of DuP734 to reverse the enhancing effect of NPY to the same extent as the ς1/ς2 antagonists suggests that NPY is acting through a ς1 or ς1-like receptor. This interpretation is supported by the inability of BIMU-8, a ς2-selective antagonist with aKi at ς2 of 20 nM (Bonhauset al., 1993), to reverse the enhancing effect of NPY.Monnet et al. (1996), using different conditions from ours, have shown that in their hands, some ς ligands can enhance [3H]norepinephrine release from rat hippocampal slices.

    Our data also show that NPY is not acting through any of the three best-characterized Y receptor subtypes to enhance DA release. NPY analogs most specific for Y1, Y2 and Y3 receptor subtypes were used at concentrations expected to occupy their preferred receptor types maximally and to occupy 20% or fewer of the nonpreferred receptors, on the basis of IC50 values previously reported (0.3 ± 0.1 nM for [Leu31,Pro34]NPY and 0.24 ± 0.1 nM for NPY13–36) (Dumont et al., 1995). [Leu31,Pro34]NPY binds to Y1 and Y3 receptors, whereas NPY13–36 binds to Y2 and Y3 receptors (Dumont et al., 1993; Fuhlendorff et al., 1990; Wahlestedt et al., 1990). Both of these peptide analogs had an enhancing effect on NMDA-stimulated DA release, which suggests that NPY could be acting through any of the three best-characterized Y receptor subtypes. However, our results indicate that the enhancing effects of NPY, [Leu31,Pro34]NPY and NPY13–36occur through different receptors and that NPY is not acting through Y1, Y2 or Y3. First, the four ς antagonists that reverse the enhancing effect of NPY do not reverse the enhancing effect of either [Leu31,Pro34]NPY or NPY13–36. Second, the use of PYY in our system had no effect on DA release. PYY differs from NPY in that it does not bind to the Y3 receptor (Grundemar et al., 1991;Wahlestedt et al., 1992). PYY binds to Y1 and Y2 with a greater affinity than NPY and does not enhance DA release as NPY does, so NPY cannot be acting through the Y1or Y2 receptor. These data support the conclusion that although the responses of NPY and NPY analogs are the same, the receptors involved are different, NPY acting through a ς1or ς1-like receptor and NPY analogs acting through Y receptors.

    The use of PYX-1 further shows that NPY may be acting via a ς1 or ς1-like receptor. PYX-1 is a nonselective Y receptor antagonist with a KD of approximately 500 nM (Tatemoto et al., 1992). We found that PYX-1 reversed the enhancing effect of NPY as well as the inhibitory effects of (+)pentazocine on NMDA-stimulated DA release. Because our results with NPY analogs and PYY suggest that NPY is acting through a ς receptor and not a currently identified Y receptor, PYX-1 may have ς antagonist properties in addition to its nonselective Y receptor antagonist properties.

    One potential explanation for the opposite effects of NPY and (+)pentazocine on NMDA-stimulated DA release is that these compounds may act as inverse agonists to one another (Milligan et al., 1995). Inverse agonism has been proposed for ς ligands (Monnetet al., 1996). Our data, in the current and previous (Ault and Werling, 1997) studies, suggest that the common receptor at which NPY and (+)pentazocine act to modulate DA release would represent an overlap between ς and Y receptors. This overlap would probably be the ς1 receptor or a receptor with ς1-like pharmacology.

    Another explanation is the involvement of multiple receptors in the regulation of DA release. NPY may enhance release by acting at an unknown Y receptor subtype that is not Y1, Y2or Y3. This receptor would not be the same as the ς receptor through which (+)pentazocine acts. Recent data from both cloning and functional studies demonstrate the existence of newly identified receptors sensitive to NPY and designated Y4(Bard et al., 1995; Gehlert et al., 1996), Y5 (Gerald et al., 1996) and Y6(Gregor et al., 1996; Matsumoto et al., 1996;Weinberg et al., 1996). It is possible one of these new Y receptors, Y4, Y5 or Y6, may be mediating the effects of NPY and ς ligands on DA release. This explanation would require PYX-1 to be an antagonist at the ς receptor in addition to the Y receptors. Similarly, the ς antagonists used in this study would have to be antagonists at this new Y receptor. Currently, we cannot eliminate either possible explanation.

    In summary, we have demonstrated that NPY enhances NMDA-stimulated DA release in slices of rat nucleus accumbens. This response probably occurs through a ς1 or ς1-like receptor; known ς1 antagonists reverse the effect. Furthermore, the response does not appear to occur through a Y1, Y2 or Y3 receptor; PYY does not produce the same effect, and ς antagonists do not reverse the enhancement of DA release by [Leu31,Pro34]NPY or NPY13–36. Our data are consistent with NPY acting as an endogenous ligand for a subtype of ς receptor with characteristics different from Y1, Y2 or Y3receptors but sensitive to PYX-1.

    Many potential therapeutic applications of NPY receptor ligands have been proposed (Wahlestedt et al., 1993). Our data suggest an additional possibility: a role in therapy of dopaminergic disorders localized to nucleus accumbens, such as psychosis and drug abuse. Haloperidol, a clinically effective and widely used antipsychotic, binds to the ς1 site with high affinity. In addition, many ς1 antagonists have been proposed as potential antipsychotic drugs. Among these are NPC16377 and DuP734, both of which had antipsychotic properties in animal models (Clissold et al., 1993; Cook et al., 1992). Our data show that NPY enhances DA release from nucleus accumbens and that DuP734 and other ς1 antagonists block the enhancement. It is possible that this mechanism accounts for the reversal of symptoms associated with psychosis in the animal models.

    Previous SectionNext Section

    Acknowledgments

    We thank Dr. Wayne Bowen and Dr. Brian DeCosta for the gift of BD1008 and BD737, Dr. Bill Tam and Dr. Rob Zaczek for the gift of DuP734 and Dr. Doug Bonhaus for the gift of BIMU-8. We also thank Dr. David Perry for his critical evaluation of the manuscript.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Linda L. Werling, Department of Pharmacology, The George Washington University Medical Center, 2300 I Street, N.W., Washington, DC 20037.

    • ↵1 This work was supported by a grant from NIDA to Linda L. Werling and a predoctoral fellowship from NIDA to David T. Ault.

    • Abbreviations:
      ANOVA
      analysis of variance
      BD737
      1S,2R-(-)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)-cyclohexylamine
      BD1008
      N-[2-(3,4-dichlorophenyl)-ethyl]-N-methyl-2-pyrrolidinyl)ethylamine
      BIMU-8
      (endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-(1-methyl)ethyl-2-oxo-1H-benzimidazole-1-carboxyamidehydrochloride
      DA
      dopamine
      DuP734
      1-(cyclopropylmethyl)-4-2′-4"-fluorophenyl)-2′-oxoethyl)piperidine HBr
      MKB
      modified Krebs-HEPES buffer
      NMDA
      N-methyl-d-aspartate
      NPY
      Neuropeptide Y
      PYX-1
      Ac-[3-(2,6-dichlorobenzyl)Tyr27,d-Thr32]NPY-(27-36) amide
      PYY
      peptide YY
      • Received June 19, 1997.
      • Accepted October 20, 1997.
    Previous Section
     

    References

    1. ↵
      1. Ault DT,
      2. Werling LL
      (1997) Differential modulation of NMDA-stimulated [3H]dopamine release from rat striatum by neuropeptide Y and ς receptor ligands. Brain Res 760:210–217.
      CrossRefMedline
    2. ↵
      1. Bard JA,
      2. Walker MW,
      3. Branchek TA,
      4. Weinshank RL
      (1995) Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 270:26762–26765.
      Abstract/FREE Full Text
    3. ↵
      1. Bonhaus DW,
      2. Loury DN,
      3. Jakeman LB,
      4. To Z,
      5. DeSouza A,
      6. Eglan RM,
      7. Wong EHF
      (1993) [3H]BIMU-8, a 5HT3 receptor ligand in NG108 cells, selectively labels sigma2 binding sites in guinea pig hippocampus. J Pharmacol Exp Ther 267:961–970.
      Abstract/FREE Full Text
    4. ↵
      1. Bouchard P,
      2. DuMont Y,
      3. Fornier A,
      4. St.Pierre S,
      5. Quirion R
      (1993) Evidence for in vivo interactions between NPY-related peptides and ς receptors in the mouse hippocampal formation. J Neurosci 13:3926–3931.
      Abstract
    5. ↵
      1. Ceci A,
      2. Smith M,
      3. French ED
      (1988) Activation of the A10 mesolimbic system by the ς receptor agonist SKF10,047 can be blocked by rimcazole, a novel putative antipsychotic. Eur J Pharmacol 154:53–57.
      CrossRefMedlineWeb of Science
    6. ↵
      1. Clissold DB,
      2. Pontecorvo MJ,
      3. Jones BE,
      4. Abreu ME,
      5. Karbon EW,
      6. Erickson RH,
      7. Natalie KJ, Jr,
      8. Borosky S,
      9. Hartman T,
      10. Mansbach RS,
      11. Balster RL,
      12. Ferkany JW,
      13. Enna SJ
      (1993) NPC 16377, a potent and selective ς ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 265:876–886.
      Abstract/FREE Full Text
    7. ↵
      1. Cook L,
      2. Tam SW,
      3. Rohrbach KW
      (1992) DuP734 [1-(cyclopropylmethyl)-4-(2′(4"-fluorophenyl)-2′-oxoethyl)piperidine HBr], a potential antipsychotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 263:1159–1166.
      Abstract/FREE Full Text
    8. ↵
      1. Dumont Y,
      2. Fournier A,
      3. St.-Pierre S,
      4. Quirion R
      (1995) Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31, Pro34]peptide YY and [125I]peptide YY13–36 as selective Y1 and Y2 radioligands. J Pharmacol Exp Ther 272:673–680.
      Abstract/FREE Full Text
      1. Dumont Y,
      2. Fournier A,
      3. St.-Pierre S,
      4. Schwartz TW,
      5. Quirion R
      (1990) Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol 191:501–503.
      CrossRefMedline
    10. ↵
      1. Dumont Y,
      2. Satoh H,
      3. Cadieux A,
      4. Taoudi-Benchekroun M,
      5. Pheng LH,
      6. St. Pierre S,
      7. Fournier A,
      8. Quirion R
      (1993) Evaluation of truncated neuropeptide Y modified in position 1 on various binding and bioassays. Eur J Pharmacol 238:37–45.
      CrossRefMedlineWeb of Science
    11. ↵
      1. Fuhlendorff J,
      2. Gether U,
      3. Aakerlund L,
      4. Langeland-Johansen N,
      5. Thogerson H,
      6. Melberg SG,
      7. Olsen UB,
      8. Thastrup O,
      9. Schwartz TW
      (1990) [Leu31, Pro34]Neuropeptide Y: A specific Y1 receptor agonist. Proc Natl Acad Sci USA 87:182–186.
      Abstract/FREE Full Text
    12. ↵
      1. Gehlert DR,
      2. Schober DA,
      3. Beavers L,
      4. Gadski R,
      5. Hoffman JA,
      6. Smiley DL,
      7. Chance RE,
      8. Lundell I,
      9. Larhammer D
      (1996) Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol Pharmacol 50:112–118.
      Abstract
    13. ↵
      1. Gerald C,
      2. Walker MW,
      3. Criscione L,
      4. Gustafson EL,
      5. Batzl-Hartmann C,
      6. Smith KE,
      7. Vaysse P,
      8. Durkin MM,
      9. Laz TM,
      10. Linemeyer DL,
      11. Schaffhauser AO,
      12. Whitebread S,
      13. Hofbauer KG,
      14. Taber RI,
      15. Branchek TA,
      16. Weinshank RL
      (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168–171.
      CrossRefMedline
    14. ↵
      1. Goldstein SR,
      2. Matsumoto RR,
      3. Thompson TL,
      4. Patrick RL,
      5. Bowen WD,
      6. Walker JM
      (1989) Motor effects of two ς ligands mediated by nigrostriatal dopamine systems. Synapse 4:254–258.
      CrossRefMedlineWeb of Science
    15. ↵
      1. Gonzalez-Alvear GM,
      2. Werling LL
      (1994) Regulation of [3H]DA release from rat striatal slices by ς receptor ligands. J Pharmacol Exp Ther 271:212–219.
      Abstract/FREE Full Text
    16. ↵
      1. Gregor P,
      2. Feng Y,
      3. DeCarr LB,
      4. Cornfield LJ,
      5. McCaleb ML
      (1996) Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J Biol Chem 271:27776–27781.
      Abstract/FREE Full Text
    17. ↵
      1. Grundemar L,
      2. Wahlestedt C,
      3. Reis DJ
      (1991) Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J Pharmacol Exp Ther 258:633–638.
      Abstract/FREE Full Text
    18. ↵
      1. Gundlach AL,
      2. Largent BL,
      3. Snyder SH
      (1986) Autoradiographic localization of ς receptor binding sites in guinea pig brain and rat central nervous system with ((+)-3H-hydroxylphenyl)-N-(1-propyl)-piperidine. J Neurosci 6:1757–1770.
      Abstract
    19. ↵
      1. Hanner M,
      2. Moebius FF,
      3. Flandorfer A,
      4. Knaus H-G,
      5. Striessnig J,
      6. Kempner E,
      7. Glossmann H
      (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93:8072–8077.
      Abstract/FREE Full Text
    20. ↵
      1. Higuchi H,
      2. Costa E,
      3. Yang H-YT
      (1988) Neuropeptide Y inhibits the nicotine-mediated release of catecholamines from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 244:468–474.
      Abstract/FREE Full Text
    21. ↵
      1. Jewett DC,
      2. Cleary J,
      3. Levine AS,
      4. Schaal DW,
      5. Thompson T
      (1992) Effects of neuropeptide Y on food-reinforced behavior in satiated rats. Pharmacol Biochem Behav 42:207–212.
      CrossRefMedlineWeb of Science
    22. ↵
      1. Jewett DC,
      2. Cleary J,
      3. Levine AS,
      4. Schaal DW,
      5. Thompson T
      (1995) Effects of neuropeptide Y, insulin, 2-deoxyglucose, and food deprivation on food-motivated behavior. Psychopharmacology Berl 120:267–271.
      CrossRefMedline
    23. ↵
      1. Josselyn SA,
      2. Beninger RJ
      (1993) Neuropeptide Y: Intraaccumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol Biochem Behav 46:543–552.
      CrossRefMedlineWeb of Science
    24. ↵
      1. Junien JL,
      2. Gue M,
      3. Bueno L
      (1991) Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin releasing factor-induced colonic motor activation in rats. Neuropharmacology 30:1119–1124.
      CrossRefMedline
    25. ↵
      1. Leitner ML,
      2. Hohmann AG,
      3. Patrick SL,
      4. Walker JM
      (1994) Regional variation in the ratio of sigma1 to sigma2 binding in rat brain. Eur J Pharmacol 259:65–69.
      CrossRefMedlineWeb of Science
    26. ↵
      1. Martin WR,
      2. Eades CG,
      3. Thompson JA,
      4. Huppler RE,
      5. Gilbert PE
      (1976) The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532.
      Abstract/FREE Full Text
    27. ↵
      1. Mash DC,
      2. Zabetian CP
      (1992) Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 12:195–205.
      CrossRefMedline
    28. ↵
      1. Matsumoto M,
      2. Nomura T,
      3. Momose K,
      4. Ikeda Y,
      5. Kondou Y,
      6. Akiho H,
      7. Togami J,
      8. Kimura Y,
      9. Okada M,
      10. Yamaguchi T
      (1996) Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J Biol Chem 271:27217–27220.
      Abstract/FREE Full Text
    29. ↵
      1. McLean S,
      2. Weber E
      (1988) Autoradiographic visualization of haloperidol sensitive sigma receptors in guinea pig brain. Neuroscience 25:259–269.
      CrossRefMedlineWeb of Science
    30. ↵
      1. Milligan G,
      2. Bond RA,
      3. Lee M
      (1995) Inverse agonism: Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16:10–13.
      CrossRefMedline
    31. ↵
      1. Monnet FP,
      2. Debonnel G,
      3. Fournier A,
      4. DeMontigny C
      (1992a) NPY potentiates the NMDA response in the CA3 hippocampus II. Involvement of a subtype of ς receptor. J Pharmacol Exp Ther 263:1219–1225.
      Abstract/FREE Full Text
    32. ↵
      1. Monnet FP,
      2. DeCosta BR,
      3. Bowen WD
      (1996) Differentiation of ς ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Brit J Pharmacol 119:65–72.
      CrossRefMedlineWeb of Science
    33. ↵
      1. Monnet FP,
      2. Fournier A,
      3. Debonnel G,
      4. deMontigny C
      (1992b) NPY potentiates selectively the NMDA response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical NPY receptor. J Pharmacol Exp Ther 263:1212–1218.
      Abstract/FREE Full Text
    34. ↵
      1. Pascaud XB,
      2. Chovet M,
      3. Roze C,
      4. Junien JL
      (1993) Neuropeptide Y and sigma receptor agonists act through a common pathway to stimulate duodenal alkaline secretion in rats. Eur J Pharmacol 2:389–394.
    35. ↵
      1. Peters J,
      2. Van Kammen DP,
      3. Gelernter J,
      4. Yao J,
      5. Shaw D
      (1990) Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr Res 3:287–294.
      CrossRefMedlineWeb of Science
    36. ↵
      1. Kameyama T,
      2. Nebeshima T,
      3. Domino EF
      1. Quirion R,
      2. Mount H,
      3. Chandieu I,
      4. Dumont Y,
      5. Boksa P
      (1991) Neuropeptide Y, polypeptide YY, phencyclidine and sigma related agents: Any relationships? in NMDA and Related Agents: Biochemistry, Pharmacology and Behavior, eds Kameyama T, Nebeshima T, Domino EF (NPP Books, Ann Arbor), pp 203–210.
    37. ↵
      1. Riviere PJM,
      2. Rao RK,
      3. Pascaud X,
      4. Junien JL,
      5. Porreca F
      (1993) Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum. J Pharmacol Exp Ther 264:1268–1274.
      Abstract/FREE Full Text
    38. ↵
      1. Roman FJ,
      2. Pascaud X,
      3. Duffy O,
      4. Vauche D,
      5. Martin B,
      6. Junien JL
      (1989) Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites. Eur J Pharmacol 174:301–302.
      CrossRefMedlineWeb of Science
      1. Salin P,
      2. Nieoullin A,
      3. Kerkerian-LeGoff L
      (1994) Reversal of the adaptive response of NPY neurons in the rat striatum to nigrostriatal dopamine deafferentiation by the NMDA antagonist dizocilpine maleate. Neuroscience 61:93–105.
      CrossRefMedline
    40. ↵
      1. Sather W,
      2. Dieudonne S,
      3. MacDonald JF,
      4. Ascher P
      (1992) Activation and desensitization of N-methyl-d-aspartate receptors in nucleated outside-out patches from mouse neurones. J Physiol 450:643–672.
      Abstract/FREE Full Text
    41. ↵
      1. Shibuya H,
      2. Mori H,
      3. Toru M
      (1992) Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 17:983–990.
      CrossRefMedline
    42. ↵
      1. Tam SW,
      2. Cook L
      (1984) Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621.
      Abstract/FREE Full Text
    43. ↵
      1. Tam SW,
      2. Mitchell KN
      (1991) Neuropeptide Y and peptide YY do not bind to brain sigma and phencyclidine receptors. Eur J Pharmacol 193:121–122.
      CrossRefMedline
    44. ↵
      1. Tam SW,
      2. Steinfels GF,
      3. Gilligan PJ,
      4. Schmidt EK,
      5. Cook L
      (1992) DuP734, a potential antipsychotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 263:1167–1174.
      Abstract/FREE Full Text
    45. ↵
      1. Tam SW,
      2. Zhang A-Z
      (1988) Sigma and PCP receptors in human frontal cortex membranes. Eur J Pharmacol 154:343–344.
      CrossRefMedlineWeb of Science
    46. ↵
      1. Tatemoto K,
      2. Mann MJ,
      3. Shimizu M
      (1992) Synthesis of receptor antagonists of neuropeptide Y. Proc Natl Acad Sci USA 89:1174–1178.
      Abstract/FREE Full Text
    47. ↵
      1. Vaupal DB
      (1982) Naltrexone fails to antagonize the sigma effects of PCP and SKF10,047 in the dog. Eur J Pharmacol 92:269–274.
    48. ↵
      1. Kamenka JM,
      2. Domino EF
      1. Vilner BJ,
      2. Bowen WD
      (1992) Characterization of sigma-like binding sites of NB41A3, S-20Y and N1E-115 neuroblastomas, C6 glioma, and NG108–15 neuroblastoma-glioma hybrid cells. in Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection, eds Kamenka JM, Domino EF (NPP Books, Ann Arbor), pp 341–353.
    49. ↵
      1. Vilner BJ,
      2. deCosta BR,
      3. Bowen WD
      (1995) Cytotoxic effects of sigma ligands: Sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15:117–134.
      Abstract
    50. ↵
      1. Allen JM,
      2. Koenig JI
      1. Wahlestedt C,
      2. Grundemar L,
      3. Hakanson R,
      4. Heilig M,
      5. Shen GH,
      6. Zukowska-Grojec Z,
      7. Reis DJ
      (1990) Neuropeptide Y receptor subtypes, Y1 and Y2. in Central and Peripheral Significance of Neuropeptide Y and Its Related Peptides, eds Allen JM, Koenig JI (New York Acad Sci, NY), 611:7–26.
    51. ↵
      1. Wahlestedt C,
      2. Regunathan S,
      3. Reis DJ
      (1992) Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life Sci 50:PL-7–PL-12.
    52. ↵
      1. Wahlestedt C,
      2. Reis DJ
      (1993) Neuropeptide Y-related peptides and their receptors—are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 32:309–352.
      CrossRef
    53. ↵
      1. Walker JM,
      2. Bowen WD,
      3. Walker FO,
      4. Matsumoto RR,
      5. deCosta B,
      6. Rice KC
      (1990) Sigma receptors: Biology and function. Pharm Rev 42:355–402.
      MedlineWeb of Science
    54. ↵
      1. Weatherspoon JK,
      2. Gonzalez-Alvear GM,
      3. Frank AR,
      4. Werling LL
      (1996) Regulation of [3H]dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophrenia Res 21:51–62.
      CrossRefMedline
    55. ↵
      1. Weinberg DH,
      2. Sirinathsinghji DJ,
      3. Tan CP,
      4. Shiao LL,
      5. Morin N,
      6. Rigby MR,
      7. Heavens RH,
      8. Rapoport DR,
      9. Bayne ML,
      10. Cascieri MA,
      11. Strader CD,
      12. Linemeyer DL,
      13. MacNeil DJ
      (1996) Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 271:16435–16438.
      Abstract/FREE Full Text
    56. ↵
      1. Weissman AD,
      2. Casanova MF,
      3. Kleinman JE,
      4. London ED,
      5. De Souza EB
      (1991) Selective loss of cerebral cortical sigma, but not PCP, binding sites in schizophrenia. Biol Psychiatry 29:41–54.
      CrossRefMedlineWeb of Science
    57. ↵
      1. Weissman AD,
      2. Su TP,
      3. Hedreen JC,
      4. London ED
      (1988) Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 247:29–33.
      Abstract/FREE Full Text
    58. ↵
      1. Werling LL,
      2. Frattali A,
      3. Portoghese PS,
      4. Takemori AE,
      5. Cox BM
      (1988) Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther 246:282–286.
      Abstract/FREE Full Text
    59. ↵
      1. Widdowson PS
      (1993) Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. Brain Res 631:27–38.
      CrossRefMedline
    60. ↵
      1. Zilberter Y,
      2. Uteshev V,
      3. Sokolova S,
      4. Khodorov B
      (1991) Desensitization of N-methyl-d-aspartate receptors in neurons dissociated from adult rat hippocampus. Mol Pharmacol 40:337–341.
      Abstract
    « Previous | Next Article »Table of Contents

    This Article

    1. JPET February 1, 1998 vol. 284 no. 2 553-560
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 331 (2)
    1. Current Issue
    1. Alert me to new issues of JPET